Pharmaceutical company Takeda is talking with the European Commission about selling an experimental inflammatory bowel disease drug to help close its US$62 billion takeover of Shire.
In a statement released Friday, October 26, Takeda stated that it has been in discussions with the EC about divesting SHP647, which is in the final stages of experimental testing for the treatment of two gastrointestinal disorders: Crohn’s disease and ulcerative colitis.
This specific drug has come to attention since Takeda already markets the drug Entyvio for those conditions. In just 2018, Entyvio sales brought Takeda US$1.8 billion.
The company claims that there are no other pharmaceuticals being discussed and that it doesn’t see any delays affecting the EC’s review being finished by its November 6 deadline.
The deal has already won approval from China, the US Federal Trade Commission, Brazil and Japan, making Europe the final major market that needs to sign off.
Full Content: Bloomberg
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI